{"schema_version":"1","generated_at":"2026-11-11T01:18:08.219Z","data_as_of":null,"url":"https://www.findmykol.com/kol/jai-joshi","json_url":"https://www.findmykol.com/kol/jai-joshi/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"jai-joshi","name":"Jai Joshi","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Tucson","state":"AZ","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1700849346","openalex":"A5047603773"},"summary":"Jai Joshi is an Oncology physician. OpenAlex indexes 14 publications with 344 citations (h-index 10).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":14,"cited_by_count":344,"h_index":10,"latest_activity_year":2023,"source":"works"},"payments":{"company_count":16,"program_years":{"first":2021,"last":null},"rows_total":18,"shown":3,"withheld":15,"rows":[{"payer":"Merck Sharp & Dohme LLC","program_year":2023,"amount_usd":19.81,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700849346"},{"payer":"Janssen Biotech, Inc.","program_year":2022,"amount_usd":174.3,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700849346"},{"payer":"Novartis Pharmaceuticals Corporation","program_year":2022,"amount_usd":156.22,"payment_count":8,"source_url":"https://openpaymentsdata.cms.gov/search?query=1700849346"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1700849346","source":"payments"},"prescribing":{"data_year":2022,"areas_total":2,"areas_shown":2,"areas":[{"area":"Cancer & immunology","share_pct":84.7,"classes_total":3,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":56.5,"drugs":[{"name":"Anastrozole","share_pct":77.1},{"name":"Letrozole","share_pct":22.9}],"max_beneficiaries":null},{"class":"Antimetabolite","setting":"prescribed","share_pct":14.1,"drugs":[{"name":"Hydroxyurea","share_pct":100}],"max_beneficiaries":null}]},{"area":"Blood & clotting","share_pct":15.3,"classes_total":1,"classes":[{"class":"Factor Xa inhibitor","setting":"prescribed","share_pct":15.3,"drugs":[{"name":"Eliquis","share_pct":100}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"facility","data_year":2022,"office_pct":15.6,"facility_pct":84.4},"source":"medicare"},"publications":{"total":14,"shown":5,"withheld":9,"matched_by":"OpenAlex author record","recent":[{"title":"Empiric Antimicrobial Regimens for Fever When Profound (< 100/μL) Granulocytopenia Persists","year":2014,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2014.56.9814","status":"verified"},{"title":"No miracles among friends","year":2014,"journal":"CHRISMED Journal of Health and Research","source_url":"https://doi.org/10.4103/2348-3334.138910","status":"verified"},{"title":"Autologous Nonfrozen Bone Marrow Transplantation after Intensive Chemotherapy: A Pilot Study","year":2009,"journal":"Acta Haematologica","source_url":"https://doi.org/10.1159/000207114","status":"verified"},{"title":"Double ?-lactam regimen compared to an aminoglycoside/?-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients","year":1993,"journal":"Supportive Care in Cancer","source_url":"https://doi.org/10.1007/bf00366445","status":"verified"},{"title":"The effect of new broad-spectrum antibiotics on faecal flora of cancer patients","year":1989,"journal":"Journal of Antimicrobial Chemotherapy","source_url":"https://doi.org/10.1093/jac/24.4.605","status":"verified"}],"source":"works"},"contact":{"address_1":"1701 W. ST. MARY'S ROAD","address_2":"SUITE 100","city":"Tucson","state":"AZ","zip":"857452620","phone":"520-585-5800","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1700849346","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":15,"publications":9}},"sources":{"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2017-03-17","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2022}},"methodology_url":"https://www.findmykol.com/about#methodology"}